Keyphrases
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
100%
High-risk Human Papillomavirus (HR-HPV)
92%
Transoral Surgery
71%
Locoregional Recurrence
41%
Odds Ratio
35%
Pack-years
30%
Surgically Treated
30%
Multi-institutional Analysis
30%
Smoking History
30%
Neuropathogenic
30%
Synaptic Elimination
30%
Surgical Ethics
30%
Cognitive Dysfunction
30%
Base of Tongue
30%
T Cells
30%
Flavivirus
30%
Nodal Disease
30%
HPV-related Oropharyngeal Cancer
30%
Lymph Node Metastasis
30%
Single Node
30%
Occult
30%
Elderly Patients
30%
Microglia
30%
Cancer Outcomes
30%
Squamous Cell Carcinoma (SqCC)
30%
Overall Survival
26%
Neck Dissection
25%
Contralateral Neck
15%
Interferon Signaling
15%
Adjuvant Therapy
15%
Neuronal Apoptosis
15%
Radiotherapy
15%
West Nile Virus
15%
West Nile Virus Infection
15%
Recurrent Disease
15%
Virus
15%
Spatial Learning
15%
Zika Virus Infection
15%
Zika Virus
15%
Surgical Resection
11%
Hazard Ratio
11%
Disease-specific Survival
11%
Primary Tumor
10%
Occult Nodal Disease
10%
Brain Function
7%
Synapse Elimination
7%
Adult Animals
7%
Never-smokers
7%
Severe Comorbidity
7%
Retrospective Cohort Study
7%
Medicine and Dentistry
Wart Virus
92%
Oropharynx Squamous Cell Carcinoma
83%
Recurrent Disease
66%
Diseases
38%
Overall Survival
33%
Microglia
30%
West Nile Virus
30%
Surgical Ethics
30%
Metastatic Carcinoma
30%
Elderly Patient
30%
Contralateral
30%
T Cell
30%
Flavivirus
30%
Cognitive Defect
30%
Squamous Cell Carcinoma
30%
Oropharynx Carcinoma
30%
Base
30%
HPV-positive Oropharyngeal Cancer
30%
Tongue
30%
Odds Ratio
25%
Comorbidity
17%
Virus Infection
15%
Disease Free Survival
15%
Spatial Learning
15%
Zika Fever
15%
Neuroapoptosis
15%
Zika Virus
15%
Disease Specific Survival
15%
Smoking
15%
Synapse
15%
Interferon
15%
Virus
15%
Surgery
12%
Neck Dissection
11%
P16
10%
Adjuvant Therapy
10%
Chemoradiotherapy
10%
Retrospective Cohort Study
10%
Radiation Therapy
9%
Lenabasum
7%
Infection
7%
Brain Function
7%
T-Cell Signaling
7%
Sequela
7%
Virus Encephalitis
7%
Hazard Ratio
7%
Cytokine Signaling
7%
Cytotoxic T-Cell
7%
Risk Stratification
7%
Drive
7%